On October 29th, “Natural Genetics” has a new tumour gene?

On October 29th, “Natural Genetics” has a new tumour gene?

Scientists and their collaborators of the Anjin subsidiary deCODE Genetics, located in Iceland, discovered six new genes with rare reproductive family mutations associated with the risk of cancer. This finding is expected to lead to better screening and treatment strategies. The results were published in the journal Nature Genetics on 29 October. This provides new ideas for early screening and treatment. Against this background, the PT/CT technology in nuclear medicine plays an important role in early tumour screening.

PET/CT combines the metabolic imaging of PET with the anatomy of CT, enabling the detection of tumours at the cell level. Cancer cells are usually metabolically active and are imaged using radioactively marked glucose (e.g. FDG), allowing PET to clearly show the tumor area. This high sensitivity imaging technique allows doctors to identify potential tumours at an early stage before tumour symptoms occur, greatly increasing the likelihood of early diagnosis.

PET/CT shows good results in the screening of multiple cancers, especially lung cancer, breast cancer and lymphoma. Through regular PET/CT examinations, it is possible to monitor minor tumor changes and intervene in a timely manner. In addition, PET/CT can be used to assess the treatment response, help doctors adjust the treatment programme and optimize the patient ‘ s treatment effectiveness.

In short, the nuclear medicine PET/CT technology has important clinical value in early tumour screening and, in combination with newly discovered genetic mutations, has opened new directions for early cancer detection and individualized treatment. Through scientific screening methods, we are expected to achieve earlier and more effective cancer management.